{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:25:35Z","timestamp":1767846335081,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T00:00:00Z","timestamp":1293753600000},"content-version":"vor","delay-in-days":244,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective.<\/jats:italic> To compare the efficacy of cabergoline (Cb2) and meloxicam in curbing vascular endothelial growth factor (VEGF) expression and preventing ovarian hyperstimulation syndrome (OHSS). <jats:italic>Design.<\/jats:italic> Randomized controlled, animal study. <jats:italic>Setting.<\/jats:italic> Academic facility<jats:italic>. Sample.<\/jats:italic> We used a total of 50 immature Wistar female rats randomly to create an experimental OHSS model. <jats:italic>Methods.<\/jats:italic> Ten rats each formed the control group and mild OHSS group. The remaining 30 were separated into three equal groups of severe OHSS. Mild and severe OHSS were induced through ovarian stimulation with gonadotropins. One group with severe OHSS was administered a low\u2010dose 100 \u03bcg\/kg Cb2 therapy; another group with severe OHSS received 600 \u03bcg\/kg meloxicam. Body weight, vascular permeability (VP), VEGF expression, ovary weight, and diameter were then compared. <jats:italic>Main outcome measures.<\/jats:italic> The efficacy of Cb2 and meloxicam for preventing OHSS. <jats:italic>Results.<\/jats:italic> Comparison of the severe OHSS groups with the controls and mild OHSS group revealed significant increases in VEGF expression, VP, ovary weight, and diameter. The increase in VEGF expression was demonstrated to be dependent on human chorionic gonadotropin doses. However, low\u2010dose Cb2 and meloxicam therapies were shown to be ineffective in decreasing VEGF expression and VP, ovary weight, and ovary diameter in severe OHSS. <jats:italic>Conclusions.<\/jats:italic> VEGF elevation played a critical part in OHSS pathogenesis, but the therapies administered failed to curb VEGF expression.<\/jats:p>","DOI":"10.3109\/00016341003592537","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T06:42:34Z","timestamp":1272436954000},"page":"692-699","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam"],"prefix":"10.1111","volume":"89","author":[{"given":"ARIF","family":"SAYLAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAGISTAN TOLGA","family":"ARIOZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TULAY","family":"KOKEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUSNIYE","family":"DILEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FILIZ","family":"SAYLAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MEHMET","family":"YILMAZER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)43508-9"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.102.010801"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220204"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg116"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0657"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.09.028"},{"key":"e_1_2_6_8_2","first-page":"157","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by human granulose and theca\/lutein cells. Role in corpus luteum development","volume":"146","author":"Kamat BR","year":"1995","journal-title":"Am J Pathol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.77.6.1723"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.6.1967"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1210\/jcem.87.7.8651","article-title":"Human chorionic gonadotropin\u2010induced ovarian hyperstimulation syndrome is associated with up\u2010regulation of vascular endothelial growth factor","volume":"87","author":"Wang TH","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_6_12_2","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen BC","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.2.263"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/87895"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-47-2-290"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(96)00063-9"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)57353-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.1.353"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.6025"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006289483"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)58153-9"},{"key":"e_1_2_6_22_2","first-page":"89","article-title":"Hormonal profile of the cycle in 68 normally menstruating women","volume":"94","author":"Landgren BM","year":"1980","journal-title":"Acta Endocrinol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.5.458"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.1.76"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.8.880"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3109%2F00016341003592537","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.3109\/00016341003592537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:34:42Z","timestamp":1698716082000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.3109\/00016341003592537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.3109\/00016341003592537"],"URL":"https:\/\/doi.org\/10.3109\/00016341003592537","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2010-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}